Table 2. Patient Characteristics (N = 163).
| N (%) | Group 1: B-HTN (N = 34) | Group 2: No HTN (N = 129) | P |
|---|---|---|---|
| Age | |||
| Median | 60 | 59 | 0.3 |
| Range | 36-85 | 33-78 | |
| Sex | |||
| Male | 15 (44) | 69 (53) | 0.33 |
| Female | 19 (56) | 60 (47) | |
| Performance status | |||
| 0 | 15 (45) | 54 (42) | 0.71 |
| 1 | 18 (53) | 75 (58) | |
| 0 or 1 (not specified) | 1 (2) | 0 (0) | |
| Stage | |||
| IV | 34 (100) | 129 (100) | 1.00 |
| CA19-9 ≥ 2 × ULN | |||
| Yes | 23 (68) | 97 (76) | 0.34 |
| No | 11 (32) | 32 (24) | |
| Baseline albumin (g/dL) | |||
| ≥ 3.4 | 28 (82) | 100 (78) | 0.78 |
| < 3.4 | 6 (18) | 29 (22) |
B-HTN indicates bevacizumab-related hypertension; HTN, hypertension; ULN, Single upper limit of normal.